Journal
OSTEOPOROSIS INTERNATIONAL
Volume 22, Issue 4, Pages 1023-1036Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s00198-010-1462-4
Keywords
Ankylosing spondylitis; Biologic therapies; Bone loss; Inflammatory joint diseases; Osteoporosis; Rheumatoid arthritis; TNF alpha blockers; Tocilizumab
Categories
Ask authors/readers for more resources
Inflammatory joint diseases are responsible of chronic systemic inflammation, joint degradations, deformities, and altered quality of life. Patients suffering from chronic rheumatic diseases also present increased bone fragility and increased fracture risk. Registration of biologic therapies has deeply modified care in rheumatic diseases, especially in rheumatoid arthritis and ankylosing spondylitis. The available biologics are the anti proinflammatory cytokine therapies (TNF alpha blockers, anakinra and tocilizumab) and the biologics active on T cell activation (abatacept and rituximab). These drugs succeeded in blocking disease activity and joint degradation. They are also able to stop systemic bone loss among patients with inflammatory rheumatic diseases. In this review, we present the current understanding of the inflammatory-induced bone loss and the skeletal effects of biologic therapies in inflammatory joint diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available